Compare BMEA & IDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | IDN |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 153.8M |
| IPO Year | 2021 | 2014 |
| Metric | BMEA | IDN |
|---|---|---|
| Price | $1.55 | $8.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $9.83 | $7.33 |
| AVG Volume (30 Days) | ★ 1.9M | 560.5K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.19 | ★ 220.00 |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $4,433,454.00 |
| Revenue This Year | N/A | $12.54 |
| Revenue Next Year | N/A | $15.32 |
| P/E Ratio | ★ N/A | $131.92 |
| Revenue Growth | N/A | ★ 23.21 |
| 52 Week Low | $0.87 | $2.47 |
| 52 Week High | $3.07 | $9.08 |
| Indicator | BMEA | IDN |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 59.20 |
| Support Level | $1.50 | $4.50 |
| Resistance Level | $1.66 | N/A |
| Average True Range (ATR) | 0.16 | 0.42 |
| MACD | -0.05 | -0.12 |
| Stochastic Oscillator | 0.00 | 39.87 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.